MedTrace Logo

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

NCT05701800 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 659

Last updated 2025-08-13

No results posted yet for this study

Summary

The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

mRNA-1468

Sterile liquid dispersion for injection

BIOLOGICAL

Placebo

Sterile liquid for injection

BIOLOGICAL

Shingrix

Sterile suspension for injection

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-23
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05701800 on ClinicalTrials.gov